Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service incontinence, prolapse & sacral neuromodulation cases in Illinois: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (219 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 38 | 2,600 | 30% |
| 2020 | 27 | 1,996 | 33% |
| 2021 | 39 |
Slings, artificial sphincter, colpopexy, sacral neuromodulation, penile prosthesis. Professional codes (what the surgeon bills): CPT 57288, 53440, 53445, 57425, 57282, 57283, 64581, 64590, 54405.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 47% of the cases CMS names in Illinois; 24 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 148 | 6,158−2.8%/yr | −2.8%/yr | 4.50.8× | 13% | 6,630 in 2030+1.2%/yr |
| BPH procedures |
Incontinence, prolapse & sacral neuromodulation in every state, and its device makers · Every procedure market in Illinois · Every state · Compare with Ohio
| 2024 |
| 2,574 |
| 47% |
| 2025 est. | ≈ 2,840 | – |
| 2026 est. | ≈ 2,970 | – |
| 2,397 |
| 37% |
| 2022 | 39 | 2,676 | 42% |
| 2023 | 45 | 2,677 | 45% |
| 2024 | 39 | 2,574 | 47% |
| 2025 from claims | – | 2,844 2,610–3,009 | 48% |
| 2026 forecast | – | 2,966 2,610–3,423 | 48% |
| 2027 forecast | – | 3,067 2,622–3,655 | 48% |
| 2028 forecast | – | 3,171 2,646–3,882 | 49% |
| 2029 forecast | – | 3,278 2,677–4,110 | 50% |
| 2030 forecast | – | 3,388 2,714–4,341 | 50% |
In 2025, 4% inpatient hospital, 89% hospital outpatient, 8% surgery center. The share outside the hospital has moved +4 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| 1,789−6.7%/yr |
| −6.7%/yr |
| 2.1 |
| 4% |
| 1,480 in 2030−3.1%/yr |
| Indiana | 18 | 1,755−4.5%/yr | −4.5%/yr | 2.5 | 16% | 1,650 in 2030−1%/yr |
| Missouri | 21 | 1,596−2.3%/yr | −2.3%/yr | 2.6 | 10% | 1,480 in 2030−1.2%/yr |
| Minnesota | 16 | 1,110+0.9%/yr | +0.9%/yr | 2.4 | 7% | 1,930 in 2030+9.7%/yr |
| Wisconsin | 13 | 1,066+0.3%/yr | +0.3%/yr | 1.9 | 3% | 1,370 in 2030+4.2%/yr |
| Kansas | 15 | 1,028−2.4%/yr | −2.4%/yr | 2.5 | 21% | 990 in 2030−0.6%/yr |
| Nebraska | 12 | 849−2%/yr | −2%/yr | 3.2 | 24% | 1,020 in 2030+3.1%/yr |
| Iowa | 7 | 604−0.6%/yr | −0.6%/yr | 1.4 | 14% | 600 in 2030−0.1%/yr |
| South Dakota | 4 | 4160%/yr | 0%/yr | 3.2 | 0% | 540 in 2030+4.4%/yr |
| 93 |
| 5,993−6.1%/yr |
| −6.1%/yr |
| 4.30.9× |
| 36% |
| 5,880 in 2030−0.3%/yr |
| Hysterectomy, hysteroscopy & ablation | 30 | 3,307−3.1%/yr | −3.1%/yr | 2.60.8× | 12% | 3,820 in 2030+2.4%/yr |
| Prostatectomy & nephrectomy | 22 | 1,462−0.6%/yr | −0.6%/yr | 1.10.8× | 0% | 1,710 in 2030+2.7%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Boston Scientific leads with 81% of company spending on these surgeons in 2025, +5 pts on 2024.
In 2025, 11 companies reported engagement with Illinois’s surgeons worth $312K in consulting, speaking, meals and travel tied to these products, about $7,995 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 46 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.